Multiple sclerosis
Not recruitingStudy on the Safety and Effectiveness of TolDec and Immunotherapy for Patients with Relapsing-Remitting Multiple Sclerosis
Study on the Safety and Effectiveness of TolDec and Immunotherapy for Patients with Relapsing-Remitting Multiple Sclerosis
- Disease:Multiple sclerosis
- Substances:Autologous tolerogenic dendritic cells
Spain- Participants:18–64 years
- Substances:Autologous tolerogenic dendritic cells
- Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer









